These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38551802)

  • 1. Estimation of health utility values for alopecia areata.
    Aggio D; Dixon C; Law EH; Randall R; Price T; Lloyd A
    Qual Life Res; 2024 Jun; 33(6):1581-1592. PubMed ID: 38551802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life of adult and adolescent patients living with alopecia areata in Australia.
    Sinclair R; Eisman S; Lee CMY; Hitschfeld M; Witcombe D; Pereira CDF
    Australas J Dermatol; 2024 Aug; 65(5):451-461. PubMed ID: 38764404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A qualitative interview study to explore adolescents' experience of alopecia areata and the content validity of sign/symptom patient-reported outcome measures.
    Macey J; Kitchen H; Aldhouse NVJ; Edson-Heredia E; Burge R; Prakash A; King BA; Mesinkovska N
    Br J Dermatol; 2022 May; 186(5):849-860. PubMed ID: 34811721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
    Br J Dermatol; 2020 Oct; 183(4):702-709. PubMed ID: 31970750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan.
    Macey J; Kitchen H; Aldhouse NVJ; Burge RT; Edson-Heredia E; McCollam JS; Isaka Y; Torisu-Itakura H
    Dermatol Ther (Heidelb); 2021 Apr; 11(2):433-447. PubMed ID: 33464474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
    Am J Clin Dermatol; 2020 Oct; 21(5):725-732. PubMed ID: 32803546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Mesinkovska N; Ko JM; King BA
    Qual Life Res; 2023 May; 32(5):1319-1327. PubMed ID: 35821174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes.
    Renert-Yuval Y; Correa da Rosa J; Garcet S; Pavel AB; Bares J; Chima M; Hawkes JE; Gilleaudeau P; Sullivan-Whalen M; Singer GK; Krueger JG; Guttman-Yassky E
    Br J Dermatol; 2022 Oct; 187(4):539-547. PubMed ID: 35656793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-Reported Burden of Severe Alopecia Areata: First Results from the Multinational Alopecia Areata Unmet Need Survey.
    Bewley A; Figueras-Nart I; Zhang J; Guerreiro M; Tietz N; Chtourou S; Durand F; Blume-Peytavi U
    Clin Cosmet Investig Dermatol; 2024; 17():751-761. PubMed ID: 38566887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Patients in Alopecia Areata Endpoint Development: Understanding Physical Signs and Symptoms.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes F; Dutronc Y; Mesinkovska NA; Ko JM; King BA
    J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S71-S77. PubMed ID: 33099392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of QOL in Patients with Alopecia Areata.
    Senna M; Ko J; Glashofer M; Walker C; Ball S; Edson-Heredia E; Zhu B; Shapiro J
    J Invest Dermatol; 2022 Oct; 142(10):2646-2650.e3. PubMed ID: 35331716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the Scalp Hair Assessment PRO™ measure for alopecia areata.
    Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
    Br J Dermatol; 2020 Dec; 183(6):1065-1072. PubMed ID: 32163589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety.
    Russo PM; Fino E; Mancini C; Mazzetti M; Starace M; Piraccini BM
    J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):608-611. PubMed ID: 30394586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity.
    ; Moussa A; Bennett M; Wall D; Meah N; York K; Bokhari L; Asfour L; Rees H; Abraham LS; Asz-Sigall D; Basmanav FB; Bergfeld W; Betz RC; Bhoyrul B; Blume-Peytavi U; Callender V; Chitreddy V; Combalia A; Cotsarelis G; Craiglow B; Dhurat R; Donovan J; Doroshkevich A; Eisman S; Farrant P; Ferrando J; Gadzhigoroeva A; Green J; Grimalt R; Harries M; Hordinsky M; Irvine A; Jolliffe V; Kaiumov S; King B; Lee J; Lee WS; Li J; Lortkipanidze N; McMichael A; Mesinkovska NA; Messenger A; Mirmirani P; Olsen E; Orlow SJ; Ovcharenko Y; Piraccini BM; Pirmez R; Rakowska A; Reygagne P; Rudnicka L; Corralo DS; Senna M; Shapiro J; Sharma P; Siliuk T; Starace M; Suchonwanit P; Takwale A; Tosti A; Vañó-Galván S; Visser WI; Vogt A; Wade M; Yip L; Zhou C; Sinclair R
    JAMA Dermatol; 2024 Mar; 160(3):341-350. PubMed ID: 38324292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between physical activity levels and symptoms of depression, anxiety and stress in individuals with alopecia Areata.
    Rajoo Y; Wong J; Cooper G; Raj IS; Castle DJ; Chong AH; Green J; Kennedy GA
    BMC Psychol; 2019 Jul; 7(1):48. PubMed ID: 31337438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychosocial impact of pediatric alopecia areata: A survey study.
    Benton S; Bellefeuille G; Rypka K; Nguyen A; Raymond O; Gorbatenko-Roth K; Maguiness S; Hordinsky MK
    Pediatr Dermatol; 2023 Mar; 40(2):312-314. PubMed ID: 36722625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata.
    Lloyd A; Aggio D; Dixon C; Law EH; Price T
    Pharmacoecon Open; 2024 Sep; 8(5):715-725. PubMed ID: 38969921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician- and Patient-Reported Severity and Quality of Life Impact of Alopecia Areata: Results from a Real-World Survey in Five European Countries.
    Vañó-Galván S; Blume-Peytavi U; Farrant P; Reygagne P; Johansson E; Reed C; Marwaha S; Durand F; Piraccini BM
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3121-3135. PubMed ID: 37889388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients.
    Paracha N; Abdulla A; MacGilchrist KS
    Health Qual Life Outcomes; 2018 Sep; 16(1):179. PubMed ID: 30208899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.